3,818 Shares in Eli Lilly and Company $LLY Acquired by Fulcrum Capital LLC

Fulcrum Capital LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 3,818 shares of the company’s stock, valued at approximately $4,103,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Moody Lynn & Lieberson LLC increased its stake in Eli Lilly and Company by 3.3% in the fourth quarter. Moody Lynn & Lieberson LLC now owns 83,620 shares of the company’s stock valued at $89,865,000 after purchasing an additional 2,657 shares during the last quarter. GFG Capital LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $100,000. MFA Wealth Services boosted its position in shares of Eli Lilly and Company by 3.8% in the fourth quarter. MFA Wealth Services now owns 1,464 shares of the company’s stock worth $1,573,000 after acquiring an additional 53 shares during the last quarter. Fifth Third Wealth Advisors LLC boosted its position in shares of Eli Lilly and Company by 2.3% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 18,962 shares of the company’s stock worth $20,378,000 after acquiring an additional 419 shares during the last quarter. Finally, Brady Martz Wealth Solutions LLC grew its holdings in Eli Lilly and Company by 55.1% in the fourth quarter. Brady Martz Wealth Solutions LLC now owns 1,131 shares of the company’s stock valued at $1,215,000 after purchasing an additional 402 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 2.0%

LLY opened at $935.85 on Friday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The stock has a market capitalization of $884.21 billion, a PE ratio of 40.78, a P/E/G ratio of 1.11 and a beta of 0.51. The firm’s fifty day moving average price is $996.24 and its 200 day moving average price is $966.65.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter last year, the company posted $5.32 earnings per share. The company’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Lilly’s oral GLP?1 weight?loss pill Foundayo (orforglipron), enabling a commercial launch (via LillyDirect) and broader patient access—this is the main growth catalyst behind recent investor enthusiasm. FDA approves Lilly’s Foundayo (PR Newswire)
• Positive Sentiment: Bank of America and other sell?side notes see Foundayo as a durable commercial opportunity (BofA called it a preferred oral GLP?1); BofA also raised its price target and reiterated a Buy rating, supporting medium?term analyst optimism. Bank of America sees Foundayo as preferred oral GLP-1
• Positive Sentiment: Street estimates see a multi?billion dollar debut for Foundayo (analyst scenarios ~ $1.5B–$2.8B in 2026) and unusually large call?option activity indicates speculative positioning for further upside from the drug launch. Foundayo Launch Could Drive Up to $2.8B (Blockonomi)
• Neutral Sentiment: Lilly agreed to acquire Centessa (deal value reported around $7.8B), diversifying Lilly’s pipeline into sleep/neuroscience — strategic for long?term growth but adds near?term integration and price?premium risk. LLY to Buy Centessa Pharmaceuticals (Zacks)
• Negative Sentiment: Policy risk: the Trump administration is proposing steep tariffs on branded drugs for companies that haven’t struck pricing deals—this raises regulatory and margin uncertainty for big pharma, including Lilly. Trump Administration Unveils Up to 100% Tariff on Branded Drugs (WSJ)
• Negative Sentiment: Competitive/marketing noise: Novo Nordisk published cross?trial comparisons claiming its oral Wegovy outperformed Foundayo, and media debate over efficacy/side?effect differences is tempering some investor enthusiasm. Novo says Wegovy pill outperforms Lilly’s Foundayo (CNBC)

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LLY. Jefferies Financial Group set a $1,300.00 price objective on Eli Lilly and Company and gave the stock a “buy” rating in a report on Friday, March 13th. Truist Financial reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Scotiabank reissued an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a report on Friday, March 6th. Finally, Leerink Partners upped their target price on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an “outperform” rating in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,222.22.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.